Accredited Investor; Access to Information. Holder represents and warrants that as of the date hereof Holder is an accredited investor within the meaning of Rule 501 of Regulation D promulgated under the Act. Holder has had the opportunity to ask questions of, and to receive answers from, appropriate executive officers of the Company with respect to the terms and conditions of the transactions contemplated hereby and with respect to the business, affairs, financial condition and results of operations of the Company. Holder has had access to such financial and other information as is necessary in order for Holder to make a fully informed decision as to investment in the Company, and has had the opportunity to obtain any additional information necessary to verify any of such information to which Holder has had access.
Accredited Investor; Access to Information. Novartis is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Novartis has been furnished with materials relating to the offer and sale of the Shares, that have been requested by Novartis, including, without limitation, Ionis’s SEC Documents, and Novartis has had the opportunity to review the SEC Documents. Novartis has been afforded the opportunity to ask Ionis and Akcea questions. Neither such inquiries nor any other investigation conducted by or on behalf of Novartis or its representatives or counsel will modify, amend or affect Novartis’ right to rely on the truth, accuracy and completeness of the SEC Documents and Ionis’s and Akcea’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. Biogen is an "accredited investor" as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Biogen has been furnished with materials relating to the offer and sale of the Shares, that have been requested by Biogen, including, without limitation, Ionis' SEC Documents, and Biogen has had the opportunity to review the SEC Documents. Biogen has been afforded the opportunity to ask questions of Ionis. Neither such inquiries nor any other investigation conducted by or on behalf of Biogen or its representatives or counsel will modify, amend or affect Biogen's right to rely on the truth, accuracy and completeness of the SEC Documents and Ionis' representations and warranties contained in this Agreement. Biogen has, with respect to all matters relating to this Agreement and the offer and sale of the Shares, not relied upon counsel.
Accredited Investor; Access to Information. Purchaser is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Purchaser has been furnished with materials relating to the offer and sale of the Shares that have been requested by Purchaser, including the SEC Documents, and Purchaser has had the opportunity to review the SEC Documents. Purchaser has been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other investigation conducted by or on behalf of Purchaser or its representatives or counsel will modify, amend or affect Purchaser’s right to rely on the truth, accuracy and completeness of the SEC Documents and the Company’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. Bxxx Capital is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments in shares presenting an investment decision like that involved in the purchase of the Shares.
Accredited Investor; Access to Information. Chiesi is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Inhibrx Common Shares. Chiesi has been afforded the opportunity to ask Inhibrx questions, and receive answers from, the officers of Inhibrx concerning this Agreement, the exhibits and schedules attached hereto and the transactions contemplated hereby, as well as Inhibrx’s business, management and financial affairs, which questions were answered to its satisfaction. Chiesi understands that such discussions, as well as any information issued by Inhibrx, were intended to describe certain aspects of Inhibrx’s business and prospects, but were not necessarily a thorough or exhaustive description. Chiesi acknowledges that any business plans prepared by Inhibrx have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. Neither such inquiries nor any other investigation conducted by or on behalf of Chiesi or its representatives or counsel will modify, amend or affect Chiesi’s right to rely on the truth, accuracy and completeness of Inhibrx’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. Each Noteholder and, to the knowledge of such Noteholder, each limited partner or shareholder of such Noteholder in the case of a Noteholder which is a limited partnership or corporation, and each partner of such Noteholder in the case of a Noteholder which is a general partnership, is an "accredited investor," as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. Each Noteholder, the general partners, limited partners and shareholders of such Noteholder, as the case may be, has had substantial experience in private securities transactions like this one, is capable of evaluating the merits and risks of an investment in the Company, and has had a full opportunity to discuss the business, management, and financial affairs of the Company with the Company's management. Each Noteholder has received all requested documents from the Company and has had a full opportunity to ask questions of, and receive answers from, the officers of the Company.
Accredited Investor; Access to Information. FULL KNOWLEDGE.
Accredited Investor; Access to Information. GSK is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. GSK has been furnished with materials relating to the offer and sale of the Shares that have been requested by GSK, including the SEC Documents, and GSK has had the opportunity to review the SEC Documents. GSK has been afforded the opportunity to ask questions of Vir. Neither such inquiries nor any other investigation conducted by or on behalf of GSK or its representatives or counsel will modify, amend or affect GSK’s right to rely on the truth, accuracy and completeness of the SEC Documents and Vir’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. Genzyme is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Genzyme has been furnished with materials relating to the offer and sale of the Shares, that have been requested by Genzyme, including, without limitation, Isis’ SEC Documents, and Genzyme has had the opportunity to review the SEC Documents. Genzyme has been afforded the opportunity to ask questions of Isis. Neither such inquiries nor any other investigation conducted by or on behalf of Genzyme or its representatives or counsel will modify, amend or affect Genzyme’s right to rely on the truth, accuracy and completeness of the SEC Documents and Isis’ representations and warranties contained in this Agreement. Genzyme has, with respect to all matters relating to this Agreement and the offer and sale of the Shares, not relied upon counsel to Isis except for the legal opinion to be delivered to Genzyme pursuant to Section 5.2(g).
